<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642794</url>
  </required_header>
  <id_info>
    <org_study_id>MR_PATHRO</org_study_id>
    <nct_id>NCT04642794</nct_id>
  </id_info>
  <brief_title>Acute Pancreatitis and Thrombosis (PATHRO)</brief_title>
  <acronym>PATHRO</acronym>
  <official_title>Management of Portoplenomesenteric Vein Thrombosis in Patients With Acute Pancreatitis : an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute pancreatitis (AP) is a pathology with high morbidity and mortality.&#xD;
      Portosplenomesenteric vein thrombosis is a well-known local complication of AP with a&#xD;
      variable incidence, which can reach up to 50% in case of severe AP. However, there is no&#xD;
      specific recommendation regarding the management of Portosplenomesenteric vein thrombosis. By&#xD;
      analogy to all venous thrombosis, the European Society of Gastroenterology recommends&#xD;
      curative anticoagulation. However, the efficacy of curative anticoagulation has never been&#xD;
      evaluated by prospective studies. In addition, bleeding complications during AP occur in&#xD;
      approximately 10% of patients and are associated with a poor prognosis.&#xD;
&#xD;
      The investigators wish to conduct an observational multi-center study with epidemiologic&#xD;
      aims, including all patients admitted for AP and with a diagnosis of portosplenomesenteric&#xD;
      vein thrombosis. The aim of this study is to evaluate the therapeutic management of these&#xD;
      patients, the efficacy and safety of anticoagulant treatment for the treatment of&#xD;
      Portosplenomesenteric vein thrombosis, and their outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will include prospectively all patients admitted for AP with a computed&#xD;
      tomography diagnosis of portosplenomesenteric vein thrombosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of anticoagulation therapy</measure>
    <time_frame>up to 12 months</time_frame>
    <description>incidence defined as : the ratio of the number of patients on curative anticoagulant therapy to the number of patients admitted with AP and portosplenomesenteric vein thrombosis during the inclusion period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the outcomes of Number of patients admitted for AP with portosplenomesenteric vein thrombosis</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality at D28</measure>
    <time_frame>Day 28</time_frame>
    <description>evaluate the hospitality mortality at D28 of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality at D90</measure>
    <time_frame>Day 90</time_frame>
    <description>evaluate the hospitality mortality at D90 of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate the hospitality mortality at 6 months of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate the hospitality mortality at 12 months of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of portal cavernoma</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of portal cavernoma of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of type 2 diabetes secondary to AP</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of type 2 diabetes secondary to AP of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of occurrence of malabsorption</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of occurrence of malabsorption of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of digestive ischemia</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of digestive ischemia of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hepatic ischemia</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of hepatic ischemia of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of pancreatic necrosis</measure>
    <time_frame>up to 12 months</time_frame>
    <description>evaluate the incidence of pancreatic necrosis of patients admitted for AP with portosplenomesenteric vein</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Necrotizing Pancreatitis</condition>
  <condition>Portosplenomesenteric Venous Thrombosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational study</intervention_name>
    <description>patients admitted for AP with portosplenomesenteric vein thrombosis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitted for AP with portosplenomesenteric vein thrombosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Patients (age &gt; 18 years) with acute pancreatitis&#xD;
&#xD;
          -  AND a diagnosis on CT injected with portal time of portosplenomesenteric vein&#xD;
             thrombosis or laminated veins (without passage of blood flow through the vessel but&#xD;
             without visible intraluminal thrombus) will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Refusal to participate in research&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GARRET Charlotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GARRET Charlotte, MD</last_name>
    <phone>0240084737</phone>
    <email>charlotte.garret@chu-nantes.fr</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute necrotizing pancreatitis</keyword>
  <keyword>acute pancreatitis</keyword>
  <keyword>pancreas disease</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>anticolagulant therapy</keyword>
  <keyword>bleeding</keyword>
  <keyword>Portosplenomesenteric Vein Thrombosis</keyword>
  <keyword>splanchic venous thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Acute Necrotizing</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

